Charles River Laboratories International (CRL) FY2025 results: revenue $4.0 billion, down 0.9% on the year

Charles River Laboratories is a non-clinical drug development partner. It breeds and supplies the research models that laboratories work with, runs the discovery and safety studies a drug candidate needs before it reaches people, and sells the testing products and manufacturing services drug makers use once a product exists. It began operating in 1947, was incorporated in 1994, completed its initial public offering in 2000, and is headquartered in Wilmington, Massachusetts. The fiscal year is typically 52 weeks, each quarter 13 weeks. There are three reportable segments.

Research Models and Services

Commercial production and sale of small research models, the supply of large research models, and the services built around them. Insourcing Solutions manages client colonies inside the client's own facilities and in the company's own vivarium space under the Charles River Accelerator and Development Lab name, covering recruitment, training, staffing and management. Genetically Engineered Models and Services performs contract breeding and related work on genetically engineered models, and Research Animal Diagnostic Services provides health monitoring and diagnostics for research models. Cell Solutions supplies customised primary cells and blood components drawn from normal and mobilised peripheral blood and bone marrow and from disease state donors.

Discovery and Safety Assessment

Regulated and non-regulated services supporting the discovery, development and regulatory-required safety testing of potential new drugs, both in vitro and in research models, with bioanalytical laboratory support, strategic non-clinical consulting and programme management. Discovery services run from identification and validation of novel targets, across small molecules, oligonucleotides, biotherapeutics and cell and gene therapies, through to candidates ready for safety assessment, using pharmacokinetics, pharmacology, non-GLP toxicity assays and predictive models to find safety problems early. During 2025 the company began combining its Discovery Services and Safety Assessment businesses into one organisation with a combined sales force.

Manufacturing Solutions

Two businesses sit here. Microbial Solutions sells in vitro methods for conventional and rapid quality control testing, including the lot release testing mandated worldwide for injectable products, through the Endosafe, Celsis and Accugenix businesses: endotoxin testing, microbial detection and identification kits, reagents, instruments, software, accessories and laboratory services for pharmaceutical, biotechnology, medical device and consumer products companies. Biologics Solutions performs specialised testing of biologics and provides contract development and manufacturing products and services.

Primates and investigations

The supply of non-human primates has been a running matter for the company. After a grand jury subpoena in February 2023, the Department of Justice and the U.S. Fish and Wildlife Service investigated several shipments of non-human primates from Cambodia in late 2022 and early 2023, with a parallel civil investigation alongside it. In the fourth quarter of fiscal 2024 the company recorded a $27 million charge reducing the carrying value of that inventory to zero. In July 2025 the Fish and Wildlife Service determined to clear the shipments for legal entry into the United States, and in August 2025 the Department of Justice advised that both the grand jury investigation and the civil investigation had been closed.

People

There were approximately 19,700 employees at 27 December 2025, among them approximately 2,400 science professionals holding advanced degrees, with approximately 18,300 full-time and approximately 1,400 part-time. Approximately 59% are in North America, 32% in Europe, 7% in Asia and 3% in other regions. Total headcount has been reduced by approximately 2% through selective hiring and restructuring, consolidating sites and reducing staffing to match the pace of demand.

From Charles River Laboratories' annual report on Form 10-K for the year ended 27 December 2025. The filing

Written from the 10-K filed 18 February 2026: read the full 10-K.